| 9714243 |
4-pyridinonetriazine derivatives as HIV integrase inhibitors |
Mark W. Embrey, Thomas H. Graham, Abbas M. Walji, Sherman T. Waddell, Tao Yu +5 more |
2017-07-25 |
$193,207,000 |
| 9707234 |
Spirocyclic hetercycle compounds useful as HIV integrase inhibitors |
Thomas H. Graham, Wensheng Liu, Tao Yu, Yonglian Zhang, Sherman T. Waddell +9 more |
2017-07-18 |
$61,300,000 |
| 9505739 |
Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
Shawn J. Stachel, Craig A. Coburn, Hao Wu |
2016-11-29 |
$117,163,000 |
| 9200001 |
Triazolyl PDE10 inhibitors |
Christopher D. Cox, Vadim Dudkin, June J. Kim, Scott D. Kuduk, Carol A. McVean +2 more |
2015-12-01 |
$65,660,000 |
| 8865701 |
Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease |
Kun Liu, Shawn J. Stachel, Craig A. Coburn, Richard Soll, Hao Wu +4 more |
2014-10-21 |
$128,538,000 |
| 8765759 |
Monocyclic CGRP receptor antagonists |
Harold G. Selnick, Ian M. Bell, Melody McWherter, Donnette D. Staas, Shawn J. Stachel +3 more |
2014-07-01 |
$58,869,000 |
| 8354545 |
3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
Shawn J. Stachel, Alessia Petrocchi |
2013-01-15 |
$88,184,000 |
| 7449599 |
Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
Craig A. Coburn, Joseph P. Vacca, David Allen Annis, Gergely M. Makara, Huw M. Nash +2 more |
2008-11-11 |
$105,074,000 |
| 7153862 |
αv integrin receptor antagonists |
Ben C. Askew, Michael J. Breslin, Mark E. Duggan, John Howard Hutchinson, Robert S. Meissner +2 more |
2006-12-26 |
$66,252,000 |
| 6693101 |
&agr;v integrin receptor antagonists |
Ben C. Askew, Michael J. Breslin, Mark E. Duggan, John Howard Hutchinson, Robert S. Meissner +2 more |
2004-02-17 |
$75,674,000 |
| 6472403 |
&agr;V integrin receptor antagonists |
Mark E. Duggan, Wasyl Halczenko, John Howard Hutchinson, Aiwen Li, Robert S. Meissner +3 more |
2002-10-29 |
$258,157,000 |
| 6358959 |
Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
Mark G. Bock, Michael A. Patane |
2002-03-19 |
$90,913,000 |
